CTOs on the Move

Windtree Therapeutics

www.windtreetx.com

 
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee`s HK, while Windtree evaluates other ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.windtreetx.com
  • 2600 Kelly Road Suite 100
    Warrington, PA USA 18976
  • Phone: 215.488.9300

Executives

Name Title Contact Details

Funding

Windtree Therapeutics raised $26.4M on 12/09/2019
Windtree Therapeutics raised $23M on 05/20/2020

Similar Companies

Intendis

Intendis is a Pine Brook, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Erytech

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.

Roha Food Colors

Roha Food Colors is a Trumbull, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

National Institute of Clinical Research

National Institute of Clinical Research is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

STERIS IMS

STERIS Instrument Management Services is a surgical device and instrument management and consulting company.